Harlan Robins Sells 492,400 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 492,400 shares of the business’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Up 0.2%

Shares of NASDAQ:ADPT opened at $22.56 on Thursday. The firm has a 50 day moving average of $19.05 and a 200-day moving average of $16.56. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $23.15. The stock has a market capitalization of $3.61 billion, a PE ratio of -68.36 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter last year, the business posted ($0.20) EPS. The company’s revenue was up 35.1% compared to the same quarter last year. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Second-quarter revenue reached $71.55 million, beating the $65.44 million analyst estimate and increasing 21.5% from the prior-year period. The result indicates continued commercial momentum for Adaptive’s immune-repertoire sequencing products. Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
• Positive Sentiment: One earnings report put the quarterly adjusted loss at $0.10 per share, narrower than the $0.13 consensus estimate and the $0.17 loss a year earlier. If this measure is used by investors, it supports the case for improving operating performance. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Neutral Sentiment: Analyst sentiment remains broadly constructive, with five Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus. However, the average price target of $20.83 is below the stock’s recent level, limiting near-term upside implied by the consensus. Adaptive Biotechnologies Receives Moderate Buy Rating
• Negative Sentiment: A separate earnings calculation reported a $0.25-per-share loss, missing the $0.13 loss estimate by $0.12. The company continues to post negative profitability metrics, including a negative net margin and return on equity, highlighting execution and path-to-profitability risks. Adaptive Biotechnologies Earnings Results
• Negative Sentiment: Insider Harlan Robins sold 492,400 shares worth approximately $10.8 million, reducing his direct stake by 37.75%. The sale was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value but may still weigh on sentiment. Adaptive Biotechnologies Insider Sale

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ADPT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. JPMorgan Chase & Co. cut their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Morgan Stanley lifted their target price on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Finally, BTIG Research reiterated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 1492 Capital Management LLC purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $1,484,000. Jupiter Asset Management Ltd. raised its position in Adaptive Biotechnologies by 33.8% in the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after acquiring an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB raised its holdings in shares of Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares during the period. Westfield Capital Management Co. LP purchased a new position in Adaptive Biotechnologies in the fourth quarter valued at approximately $65,942,000. Finally, Jennison Associates LLC lifted its stake in Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after purchasing an additional 1,363,181 shares during the last quarter. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.